<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067595</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006202</org_study_id>
    <secondary_id>NCI-2019-07698</secondary_id>
    <secondary_id>10276</secondary_id>
    <nct_id>NCT05067595</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease</brief_title>
  <official_title>A Randomized, Controlled, Phase I Study of Fecal Microbiota Transplant and Dietary Fiber Supplementation in Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies how well fecal microbiota transplant and dietary fiber&#xD;
      supplementation work in treating patients with gut graft versus host disease. Fecal&#xD;
      microbiota transplant entails inoculating donor stool into a recipient's gastrointestinal&#xD;
      tract. Changing the gut microbiome by fecal microbiota transplant and fiber supplementation&#xD;
      may help treat gut graft versus host disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are randomized to 1 of 4 arms.&#xD;
&#xD;
      ARM I: Patients undergo lower FMT via colonoscopy on day 0. Patients also receive fiber&#xD;
      supplementation PO daily on days 1-42.&#xD;
&#xD;
      ARM II: Patients undergo lower FMT via colonoscopy on day 0.&#xD;
&#xD;
      ARM III: Patients receive upper FMT capsules PO over 2 days. Patients also receive fiber&#xD;
      supplementation PO daily on days 0-41.&#xD;
&#xD;
      ARM IV: Patients receive upper FMT capsules PO over 2 days.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 180 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial composition of stool</measure>
    <time_frame>At baseline</time_frame>
    <description>Analyses will consist of summary statistics of the bacterial diversity in the microbiome (e.g., the alpha diversity, the abundance of bacterial species associated with protection from graft versus host disease [GvHD]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial composition of stool</measure>
    <time_frame>At day 28 after fecal microbiota transplant</time_frame>
    <description>Analyses will consist of summary statistics of the bacterial diversity in the microbiome (e.g., the alpha diversity, the abundance of bacterial species associated with protection from graft versus host disease [GvHD]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial genes in stool</measure>
    <time_frame>At baseline</time_frame>
    <description>Specifically abundance of genes related to fiber fermentation and short chain fatty acids (SCFA) production metabolites in stool, specifically short chain fatty acids will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial genes in stool</measure>
    <time_frame>At day 28 after fecal microbiota transplant</time_frame>
    <description>Specifically abundance of genes related to fiber fermentation and short chain fatty acids (SCFA) production metabolites in stool, specifically short chain fatty acids will be assessed.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Intestinal Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Arm I (lower FMT, fiber supplementation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo lower FMT via colonoscopy on day 0, and receive upper FMT capsules PO over 2 days. Patients also receive fiber supplementation PO daily on days 1-42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (lower FMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo lower FMT via colonoscopy on day 0, and receive upper FMT capsules PO over 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (upper FMT, fiber supplementation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive upper FMT capsules PO over 2 days. Patients also receive fiber supplementation PO daily on days 0-41.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (upper FMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive upper FMT capsules PO over 2 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>Undergo lower FMT via colonoscopy</description>
    <arm_group_label>Arm I (lower FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm II (lower FMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Given upper FMT PO</description>
    <arm_group_label>Arm I (lower FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm II (lower FMT)</arm_group_label>
    <arm_group_label>Arm III (upper FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm IV (upper FMT)</arm_group_label>
    <other_name>Fecal Material Transplantation</other_name>
    <other_name>Fecal Transplantation</other_name>
    <other_name>FMT</other_name>
    <other_name>Poo Transplant</other_name>
    <other_name>Poop Transplant</other_name>
    <other_name>Stool Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Undergo lower FMT via colonoscopy</description>
    <arm_group_label>Arm I (lower FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm II (lower FMT)</arm_group_label>
    <other_name>Fecal Material Transplantation</other_name>
    <other_name>Fecal Transplantation</other_name>
    <other_name>FMT</other_name>
    <other_name>Poo Transplant</other_name>
    <other_name>Poop Transplant</other_name>
    <other_name>Stool Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional Supplementation</intervention_name>
    <description>Given dietary fiber supplementation PO</description>
    <arm_group_label>Arm I (lower FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm III (upper FMT, fiber supplementation)</arm_group_label>
    <other_name>Supplementation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (lower FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm II (lower FMT)</arm_group_label>
    <arm_group_label>Arm III (upper FMT, fiber supplementation)</arm_group_label>
    <arm_group_label>Arm IV (upper FMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of allogeneic hemopoietic stem cell transplant in the past 100 days&#xD;
&#xD;
          -  Post-engraftment, defined by three consecutive days of sustained neutrophil&#xD;
             engraftment with an absolute neutrophil count of at least 500 cells/mm^3&#xD;
&#xD;
          -  Moderate to severe acute GI GvHD stage 2 or higher as measured by the modified&#xD;
             Glucksberg criteria and averaged over 3 consecutive days. In patients who have already&#xD;
             had GI biopsy, biopsy histology must be compatible with GVHD, although biopsy is not&#xD;
             required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous serious adverse events associated with FMT&#xD;
&#xD;
          -  History of bowel perforation&#xD;
&#xD;
          -  History of bowel resection&#xD;
&#xD;
          -  History of intestinal obstruction&#xD;
&#xD;
          -  History of gastric bypass&#xD;
&#xD;
          -  History of diverticulitis&#xD;
&#xD;
          -  History of inflammatory bowel disease (i.e. Crohn's disease and ulcerative colitis)&#xD;
&#xD;
          -  History of celiac disease confirmed by serologic testing or small bowel biopsy&#xD;
&#xD;
          -  History of severe dietary allergy as designated by World Allergy Organization&#xD;
             Subcutaneous Immunotherapy Systemic Reaction Grading System grade 2 or more&#xD;
&#xD;
          -  Current evidence of mechanical obstruction of the bowel&#xD;
&#xD;
          -  Known allergies to sodium chloride, glycerol, theobroma oil, hide bovine gelatin,&#xD;
             sodium lauryl sulfate, colorants FD&amp;C, or titanium dioxide&#xD;
&#xD;
          -  Currently pregnant, planning to become pregnant or breastfeeding during the study&#xD;
             period. Women of childbearing potential (those who are not post-menopausal or&#xD;
             post-hysterectomy) must be negative for pregnancy per urine pregnancy test at&#xD;
             enrollment&#xD;
&#xD;
          -  Individuals with the ability to conceive children who are not willing to abstain from&#xD;
             sexual activity or use an effective form of birth control during the duration of the&#xD;
             study&#xD;
&#xD;
          -  Unwilling or unable to participate in study procedures including oral intake of FMT,&#xD;
             colonoscopy, fiber supplementation, collection of stool samples and completion study&#xD;
             surveys&#xD;
&#xD;
          -  Cannot reasonably and safely participate in the study in the opinion of the&#xD;
             investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Fredricks</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Fredricks</last_name>
    <phone>206.667.1935</phone>
    <email>dfredric@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Fredricks</last_name>
      <phone>206-667-1935</phone>
      <email>dfredric@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>David Fredricks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

